+39 02 610346.1 - info@newron.com

Latest press releases

  • 17May
    Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age


  • 12May
    Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago® (safinamide)


  • 11Apr
    Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada

  • 10Apr
    ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease


  • 5Apr
    Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia

  • 28Mar
    Newron Shareholders Confirm Company Management


View All

Newron share price


  • 15Jun
    Mediscience awards: Newron is 2017 break through award winner

  • 27Nov
    German Equity Forum 2017

    Nov, 27-29, 2017 - Frankfurt

  • 15Nov
    Jefferies 2017 London Healthcare Conference

    Nov, 15-16, 2017 - Waldorf Hilton, London

View Event Calendar